Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Uveal Melanoma 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1

Interventions

Sorafenib 29Nivolumab 15pembrolizumab 12Radiosurgery 9Bevacizumab 9atezolizumab 7regorafenib 5Radiotherapy 5Fluorouracil 5Doxorubicin 5lenvatinib 4Sunitinib 4Oxaliplatin 4Ipilimumab 4Gemcitabine 4Ethiodized Oil 4Erlotinib Hydrochloride 4Capecitabine 4TLC 388 3Radiofrequency Ablation 3Leucovorin 3Everolimus 3Cisplatin 3Blood Specimen Collection 3toripalimab 2phosphomannopentaose sulfate 2durvalumab 2cediranib 2avelumab 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Hepatocellular × ADI PEG20 × Clear all
NCT02102022 2022-04-25

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Polaris Group

Phase 1/2 Terminated
140 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02029690 2020-09-25

TRAP

Polaris Group

Phase 1 Terminated
85 enrolled
CNSDermatologicGastrointestinal

Uveal Melanoma, Carcinoma, Glioma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡